You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Baxter
Boehringer Ingelheim
Harvard Business School
AstraZeneca
Johnson and Johnson
McKesson

Last Updated: May 10, 2021

DrugPatentWatch Database Preview

Litigation Details for THERAPEUTICSMD, INC. v. TEVA PHARMACEUTICALS USA, INC (D.N.J. 2020)

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

THERAPEUTICSMD, INC. v. TEVA PHARMACEUTICALS USA, INC (D.N.J. 2020)

Docket   Get Started for $10 Date Filed 2020-04-01
Court District Court, D. New Jersey Date Terminated
Cause 15:1126 Patent Infringement Assigned To Brian R. Martinotti
Jury Demand None Referred To Edward S. Kiel
Parties THERAPEUTICSMD, INC.
Patents 10,052,386; 10,206,932; 10,258,630; 10,398,708; 10,471,072; 10,537,581; 10,568,891; 8,633,178; 8,846,648; 8,846,649; 8,987,237; 8,993,548; 8,993,549; 9,006,222; 9,114,145; 9,114,146; 9,180,091; 9,289,382; 9,301,920
Attorneys LIZA M. WALSH
Firms Saul Ewing Arnstein & Lehr LLP
Link to Docket External link to docket
Small Molecule Drugs cited in THERAPEUTICSMD, INC. v. TEVA PHARMACEUTICALS USA, INC
The small molecule drugs covered by the patents cited in this case are   Get Started for $10 and   Get Started for $10 .
Biologic Drugs cited in THERAPEUTICSMD, INC. v. TEVA PHARMACEUTICALS USA, INC
The biologic drug covered by the patents cited in this case is   Get Started for $10 .

Details for THERAPEUTICSMD, INC. v. TEVA PHARMACEUTICALS USA, INC (D.N.J. 2020)

Date Filed Document No. Description Snippet Link To Document
2020-04-01 1 Complaint Exhibit B), U.S. Patent No. 10,258,630 (“the ’630 patent”) (attached as Exhibit C), U.S. Patent No. 10,398,708…involving U.S. Patent No. 9,180,091 (“the ’091 patent”) (attached as Exhibit A), U.S. Patent No. 9,289,382…the ’708 patent”) (attached as Exhibit D), and U.S. Patent No. 10,471,072 (“the ’072 patent”) (attached…’072 patents. The ’091, ’382, ’630, ’708, and ’072 patents are five (5) of the seven (7) patents listed…before the patent expiration of the ’581 patent. As indicated in FDA’s Orange Book, the patent expiration External link to document
2020-12-20 52 Counterclaim AND Answer to Complaint 9,301,920, U.S. Patent No. 10,052,386, U.S. Patent No. 10,206,932, U.S. Patent No. 10,639,375…U.S. Patent No. 10,806,697 (“the ’697 patent”) and U.S. Patent No. 10,835,487 (“the ’487 patent”) are….S. Patent No. 10,806,697 (“the ’697 patent”) and U.S. Patent No. 10,835,487 (“the ’487 patent”) either….S. Patent No. 10,806,697 (“the ’697 patent”) and U.S. Patent No. 10,835,487 (“the ’487 patent”). … Patent No. 9,006,222, U.S. Patent No. 9,114,145, U.S. Patent No. 9,114,146, U.S. Patent No External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Dow
Merck
McKesson
Colorcon
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.